Press Releases July 30, 2026 05:58 AM

Red Cat Receives $2.49 Million U.S. Air Force Order for Black Widow Systems

Red Cat's Teal Drones Subsidiary Wins $2.49 Million U.S. Air Force Contract for Black Widow UAV Systems

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
RCAT

Red Cat Holdings, Inc., through its subsidiary Teal Drones, secured a $2.49 million firm-fixed-price contract from the U.S. Air Force for Black Widow small unmanned aircraft systems, including training and support. This contract supports a technical and operational assessment aiming to potentially replace the Air Force Security Forces' current Teal 2 fleet, reinforcing Red Cat's position in military drone reconnaissance technology.

Red Cat Receives $2.49 Million U.S. Air Force Order for Black Widow Systems
RCAT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Red Cat's Teal Drones subsidiary awarded $2.49M U.S. Air Force contract for Black Widow UAVs and support.
  • The contract involves a technical and operational assessment for potential replacement of the Air Force Security Forces' Teal 2 drones.
  • Black Widow is already the selected platform for the U.S. Army’s Short Range Reconnaissance Program, expanding Red Cat's presence in defense drone markets.

SALT LAKE CITY, July 30, 2026 (GLOBE NEWSWIRE) -- Red Cat Holdings, Inc. (Nasdaq: RCAT) (“Red Cat” or the “Company”), a U.S.-based provider of advanced all-domain drone and robotic solutions for defense and national security, today announced that its Teal Drones subsidiary has received a $2.49 million firm-fixed-price contract from the U.S. Air Force for Black Widow™ small unmanned aircraft systems, training and related support.


The award includes Black Widow systems, train-the-trainer support, batteries, spares and shipping. According to the contract, the equipment will be used to conduct a technical and operational assessment of Black Widow as a potential successor to the Air Force Security Forces’ current Teal 2 fleet.

The customer organization is the U.S. Air Force Security Forces Center (AFSFC), which trains, equips, and managed program execution for the Air Force Security Forces enterprise worldwide. This encompasses active-duty, Air National Guard, and Air Force Reserve Defenders. This technical and operational assessment positions Black Widow as a potential successor across the total AFSFC’s Teal 2 fleet, building on Red Cat’s momentum as the U.S. Army’s selected Short Range Reconnaissance platform.

"We are proud to support the U.S. Air Force across active-duty, Air National Guard, and reservists, as the AFSFC evaluates Black Widow for missions at the tactical edge," said Jeff Thompson, CEO of Red Cat. "This assessment of the Black Widow reflects growing recognition across the Department of War that secure, American-made systems are essential for the operations our national defense and security organizations carry out every day."

Black Widow is Red Cat’s flagship short-range reconnaissance system and the U.S. Army’s selected platform for its Short Range Reconnaissance Program. The system is designed to provide warfighters with rapidly deployable intelligence, surveillance and reconnaissance capabilities.

The contract calls for delivery by August 24, 2026.

About Red Cat Holdings, Inc.

Red Cat (Nasdaq: RCAT) is a U.S.-based provider of advanced all-domain drone and robotic solutions for defense and national security. Through its integrated portfolio of trusted U.S. and allied hardware and software, Red Cat supports military, government, and public safety operations across air, land, sea and space. Its systems span small unmanned aircraft systems, uncrewed surface vessels, wireless power transfer technology, and autonomous swarming software to enhance situational awareness, operational effectiveness, and mission safety. Learn more at www.redcat.red.

Safe Harbor Forward-Looking Statements

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Red Cat Holdings, Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. These and other risks and uncertainties are described more fully in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Red Cat Holdings, Inc. undertakes no duty to update such information except as required under applicable law.

Investor Contact:

Ankit Hira
Solebury Strategic Communications for Red Cat Holdings, Inc.
E-mail: [email protected]

Media Contact:
Peter Moran
Phone: (347) 880-2895
Email: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/98ef5dd0-3892-4401-a3aa-efe14164daee


Risks

  • The contract is an assessment, not a guaranteed full-scale adoption, introducing uncertainty in future orders.
  • Dependence on government military contracts, which can be subject to budget fluctuations and policy changes.
  • Potential technological or operational challenges in meeting the U.S. Air Force requirements within the delivery timeline.

More from Press Releases

Stantec joint venture selected by U.S. Army Corps of Engineers to advance coastal resilience on Charleston’s peninsula Jul 30, 2026 Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights Jul 30, 2026 Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing Jul 30, 2026 Mobilicom Secures New Design Win for AI-Enabled Autonomous Weapon Systems Jul 30, 2026 Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109 Jul 30, 2026